{"id":"latanoprost-plus-adjunctive-glaucoma-medication","safety":{"commonSideEffects":[{"rate":"25-35","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Iris pigmentation increase"},{"rate":"5-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Foreign body sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, increasing conventional and uveoscleral drainage of aqueous humor and thereby reducing intraocular pressure. The adjunctive glaucoma medication works through a complementary mechanism (likely beta-blocker, alpha-agonist, or carbonic anhydrase inhibitor) to provide additive IOP reduction. This combination approach targets multiple pathways of aqueous humor dynamics.","oneSentence":"Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:42.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT00735449","phase":"PHASE4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":204},{"nctId":"NCT00759941","phase":"PHASE4","title":"A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Glaucoma","enrollment":86},{"nctId":"NCT00698945","phase":"PHASE4","title":"Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Latanoprost plus adjunctive glaucoma medication","genericName":"Latanoprost plus adjunctive glaucoma medication","companyName":"Sight Sciences, Inc.","companyId":"sight-sciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}